Industry Leader

Industry Leader articles are written by executives at biopharma companies, consultancies, research firms, and companies that provide services or products to sponsors. The topics are nonpromotional and focused on industrywide business issues.

  • Sponsor Interest In Current Phase 1 Trends

    We asked respondents their level of agreement regarding several trends in the Phase 1 space to assess the direction in which their organization’s interest is heading.

  • How To Overcome Bottlenecks To Expedite Drug Approvals

    For most drug developers, the question remains: How can we accelerate delivering new drugs to patients, while at the same time, ensuring those drugs meet stringent regulatory requirements? Here are some tips that may help.

  • Virtual Marking: A Flexible Option For Pharmaceuticals

    Although virtual marking has been available for nearly a decade, courts have provided little specific guidance. Still, there are some points to keep in mind for virtual marking.

  • Realizing The Value Of Quantum Computing In Life Sciences

    In the life sciences sector, quantum computing holds great potential for transforming data-heavy processes, from accelerating drug discovery to simulating clinical trials, and is one of the key technological areas we predict will impact life sciences for the better.

  • How To Prepare For The Next Healthcare Crisis That We Don’t See Coming

    Given everything that we have learned from the COVID-19 situation,  healthcare leaders can implement the following key takeaways to help them successfully weather the next storm that comes our way.

  • Do Biobanks Need New Strategies?

    Precision medicine necessitates precision research, which necessitates getting highly specific biospecimens to researchers on demand, in alignment with their demand. Researchers shouldn’t have to adjust their research to whatever specimens are available; supply needs to fit the research.

  • Building A Legacy With Complex Assets

    For life science executives, deciding how to manage your overall portfolio, including illiquid or complex assets, is an important step in preserving both your financial and philanthropic legacies.

  • How We Landed In The International Space Station

    Looking back, it’s ironic that we named our company LaunchPad Medical. Our inspiration for the name came from our plan to take challenging ideas and materials and “launch” them into the medical space to revolutionize healthcare. But it never dawned on me to take our research to the International Space Station (ISS).

  • Taking A Strengths-Based Approach To Diversity & Inclusion

    Organizations and their leaders often focus on what needs to improve, but research shows there is more to be gained from a strengths-based approach. Coaching around strengths yields greater optimism and success.

  • 6 Tips For Contracting Or Seeking Funding From The Federal Government

    With the right preparation and investments, entering the federal government market can lead to considerable growth and visibility for your company. Consider the following tips for increased chances of success.


  • We Need To Expand How We Value Companies

    During an interview for an upcoming feature in Life Science Leader, Sanjeev Redkar, Ph.D., cofounder and president of Apollomics (a biopharmaceutical company discovering and developing oncology treatments), discussed the topic of an exit strategy.

  • Have You Heard Of The Chinese Biopharmaceutical Association (CBA)?

    While working at his first job at Human Genome Sciences in 1995, Guo-Liang Yu, Ph.D., decided to create The Chinese Biopharmaceutical Association (CBA), one of the largest Chinese American professional associations in the U.S.

  • What 4 Biopharma CFOs Think About The Future Of Remote Work

    While we touch on remote work in Life Science Leader’s annual outlook issue, the responses in this article from four biopharmaceutical CFOs to questions on the subject shed additional light on the challenge that lies ahead for employers.